VCs, Researchers, Vendors Agree: When It Comes to Funding, Arrays Face Difficult Times | GenomeWeb

By Justin Petrone

Cutbacks in federal funding, increased adoption of next-generation sequencing, and cautiousness from investors are all factors negatively influencing the financial environment for microarray technology, according to those familiar with the market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.